We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Just 7 cents out of every dollar spent on healthcare goes for brand drugs, according to a new PhRMA website that provides detailed information on the drug development process and answers critics of the pharmaceutical industry.
A Justice Department investigation of a supply services company that negotiates purchasing contracts for hospitals and other facilities may be a precursor to a broader probe to determine whether healthcare entities are overcharging the Medicare program.
Gambro Healthcare U.S., a renal care product manufacturer, has reached a preliminary agreement with the Justice Department to settle charges that it defrauded Medicare.
The Securities and Exchange Commission (SEC) has worked out a settlement with Vaso Active Pharmaceuticals and its chief executive over alleged misrepresentations made by the company.
Stiff penalties contained in a Securities and Exchange Commission (SEC) order against Bristol-Myers Squibb (BMS) could be a harbinger of future crackdowns on drug manufacturers by the commission, as well as other federal agencies, according to drug industry observers.
Amendments intended to protect Australia’s low-cost Pharmaceutical Benefits Scheme (PBS) potentially could jeopardize the U.S.-Australia free trade agreement (FTA) that has been ratified by both countries.
Pharmaceutical reforms in Japan may encourage greater use of generic drugs, but regulatory and cultural barriers still present obstacles to foreign manufacturers seeking to break into the Japanese generic market, an analyst said.
GlaxoSmithKline (GSK) and Gilead Sciences have received FDA approval for the first brand fixed-dose combination (FDC) AIDS drugs, which will treat AIDS patients in the U.S. and in developing countries.